BioCryst Pharmaceuticals Files 8-K on Financials
Ticker: BCRX · Form: 8-K · Filed: Feb 24, 2025 · CIK: 882796
Sentiment: neutral
Topics: financial-results, regulation-fd, corporate-filing
TL;DR
BioCryst dropped an 8-K on Feb 24th covering financials and other events. Check it out.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on February 24, 2025, reporting on its results of operations and financial condition. The filing also included disclosures under Regulation FD and other events, along with financial statements and exhibits. The company is incorporated in Delaware and headquartered in Durham, North Carolina.
Why It Matters
This 8-K filing provides crucial updates on BioCryst Pharmaceuticals' financial performance and operational status, which can influence investor decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- February 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Principal Executive Offices
- 919-859-1302 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
Are there any significant new events or disclosures mentioned in the 8-K?
The filing lists 'Regulation FD Disclosure' and 'Other Events' as items covered, alongside financial information.
What is the primary business of BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, SIC code 2836.
When was this 8-K filing submitted?
The filing was submitted on February 24, 2025.
Where is BioCryst Pharmaceuticals, Inc. headquartered?
The company's principal executive offices are located at 4505 Emperor Boulevard, Suite 200, Durham, North Carolina 27703.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).